Search

Your search keyword '"Li, Hua-Fei"' showing total 24 results
Start Over Author "Li, Hua-Fei"
24 results on '"Li, Hua-Fei"'

17. Enhanced Performance of E-Bike Motive Power Lead–Acid Batteries with Graphene as an Additive to the Active Mass

Author

Hu, Hai-Yan, primary, Xie, Ning, additional, Wang, Chen, additional, Wang, Li-Ya, additional, Privette, Robert M., additional, Li, Hua-Fei, additional, Pan, Ming, additional, Wu, Fan, additional, Yan, Xiao-Ling, additional, Jiang, Bang-Bang, additional, Wu, Marvin H., additional, Vinodgopal, Kizhanipuram, additional, and Dai, Gui-Ping, additional

Published
2018
Full Text
View/download PDF

20. [Biological response of B-cell lymphoma cells in vitro to 131I-rituximab]

Author

Li, Wei, Rong-cheng, Luo, Jun-yi, Zhang, Xiao, Yan, Yong-xin, Fang, and Li-hua, Fei

Subjects
Iodine Radioisotopes, Antibodies, Monoclonal, Murine-Derived, Lymphoma, B-Cell, Cell Line, Tumor, Cell Cycle, Antibodies, Monoclonal, Humans, Apoptosis, Radioimmunotherapy, Antigens, CD20, Flow Cytometry, Rituximab, Cell Proliferation
Abstract

To study the biological response of B-cell lymphoma cells positive for CD20 expression to (131)I-labeled rituximab.Anti-CD20 monoclonal antibody rituximab was labeled with (131)I by means of IODO-GEN method, and its effects on apoptosis of Raji cells were determined by Annexin-V/PI double-labeled cytometry. Its effects on the cell cycles was evaluated by cytometry with PI staining.The cell apoptosis rate measured by Annexin v-FITC/PI was 51.99% in (131)I-rituximab group, significantly higher than that in (131)I group, rituximab group and control group (42.71%, 29.42% and 26.17%, respectively, P;0.05). The apoptosis rate by flow cytometry with PI staining was 4.32% in (131)I-rituximab group, also significantly higher than that in the other 3 groups (1.47%, 1.39% and 0.37%, respectively, P0.05). Cell cycle alteration of Raji cells occurred in (131)I-rituximab group, and the majority of cells were arrested at G(1)/G(2) stage.(131)I-rituximab can regulate the cell cycle of Raji cells and induce their apoptosis to inhibit their proliferation.

Published
2006

23. Synthesis of Three-Dimensional Nanocarbon Hybrids by Chemical Vapor Deposition

Author

Dai, GuiPing, Li, Hua-Fei, and Deng, Shuguang

Subjects
Technology & Engineering / Materials Science
Abstract

Carbon nanomaterials such as graphene, carbon nanotube (CNT), and carbon nanofiber (CNF) have received tremendous attentions in the past two decades due to their extraordinary mechanical strength and thermal and electrical properties. Recently, it indicates that three-dimensional (3D) nanocarbon hybrids overcome the weakness of individual low-dimensional nanocarbon materials and exhibit unique properties among carbon nanomaterials. Efforts have thus been made to acquire synergistic integration of one-dimensional (1D) and two-dimensional (2D) carbon nanomaterials. Meanwhile, chemical vapor deposition (CVD) is a widespread and effective method of fabricating three-dimensional nanocarbon hybrids compared with other synthetic methods. In this case, a number of 3D nanocarbon hybrids are synthesized by using different precursors at diverse temperature, and the nanocarbon hybrids are expected to be a promising choice for various application areas in the future.

Published
2022

24. Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.

Author

Li HF, Wu C, Chen T, Zhang G, Zhao H, Ke CH, and Xu Z

Subjects
Antibodies, Monoclonal chemistry, Antibodies, Monoclonal pharmacokinetics, Antibodies, Monoclonal pharmacology, Cell Line, Tumor, Humans, Polyethyleneimine chemistry, Polyethyleneimine pharmacokinetics, Polyethyleneimine pharmacology, Antigens, CD20 drug effects, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents pharmacology, Lymphoma, Nanomedicine methods, Nanostructures chemistry, Rituximab chemistry, Rituximab pharmacokinetics, Rituximab pharmacology
Abstract

The CD20-directed monoclonal antibody rituximab (RTX) established a new era in the treatment of non-Hodgkin lymphoma (NHL); however, suboptimal response and/or resistance to RTX still limit its clinical merits. Although four effector mechanisms are validated to participate in CD20-based immunotherapy, including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, caspase-dependent apoptosis, and lysosome-mediated programmed cell death (PCD), they could hardly be synchronously activated by any anti-CD20 mAb or mAb derivative until now. Herein, a novel mAb nanocomb (polyethylenimine polymer-RTX-tositumomab [PPRT nanocomb]) was firstly constructed through mass arming two different anti-CD20 mAbs (RTX and tositumomab) to one polymer by nanotechnology. Comparing with free mAbs, PPRT nanocomb possesses a comparable binding ability and reduced "off-rate" to surface CD20 of NHL cells. When treated by PPRT nanocomb, the caspase-dependent apoptosis was remarkably enhanced except for concurrently eliciting complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and lysosome-mediated PCD. Besides, "cross-cell link"-assisted homotypic adhesion by PPRT nanocomb further enhanced the susceptibility to PCD of lymphoma cells. Pharmacokinetic assays revealed that PPRT nanocomb experienced a relatively reduced clearance from peripheral blood compared with free antibodies. With the cooperation of all the abovementioned superiorities, PPRT nanocomb exhibits exceptionally excellent in vivo antitumor activities in both disseminated and localized human NHL xenotransplant models.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results